(HealthDay News) — For patients undergoing urologic oncology procedures, use of the da Vinci single-port (SP) robotic system is perceived more favorably than a multiport platform, according to a study published in Urology Practice.
Luca A. Morgantini, MD, from the University of Illinois at Chicago, and colleagues administered the Patient Scar Assessment Questionnaire to patients who underwent an SP urologic procedure (n=104) or a multiport platform (Xi) urologic procedure (n=78). Scar appearance, consciousness, satisfaction with appearance, and satisfaction with symptoms were assessed. Higher scores represented worse outcomes.
SP procedure recipients reported significantly better cosmetic scar appearance compared with Xi procedure recipients (mean, 13.84 vs 15.28). The SP group also had significantly better consciousness of their surgical scar than the Xi group (mean, 8.80 vs 9.87) and higher satisfaction with the cosmetic appearance of their surgical scar (mean, 11.35 vs 12.54). Although the SP group had lower scores on satisfaction with symptoms than the Xi group, the difference was not significant (mean, 6.58 vs 6.74).
“Our findings demonstrate a correlative improvement in patient-reported outcomes related to scar aesthetics, scar-related self-consciousness, and satisfaction with scar aesthetics in patients receiving SP urologic oncology procedures compared to those receiving multi-port urologic oncology procedures,” the authors wrote.
One author disclosed financial ties to Intuitive, the manufacturer of the da Vinci single-port robotic system.